MedTrace Logo

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

NCT00819195 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2013-10-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.

Conditions

Interventions

DRUG

Glatiramer acetate

20 mg daily subcutaneous injection. Six-month duration.

Sponsors & Collaborators

Principal Investigators

  • Scott S. Zamvil, M.D. Ph.D. · UCSF Department of Neurology

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00819195 on ClinicalTrials.gov